A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.
Clinical Trial Grant
Administered By
Neurology, Behavioral Neurology
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
April 1, 2015
End Date
December 31, 2019
Administered By
Neurology, Behavioral Neurology
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
April 1, 2015
End Date
December 31, 2019